Magnetic nanoradiotracers for targeted neutrophil detection in pulmonary arterial hypertension
dc.contributor.author | Fadón Padilla, Lucía | |
dc.contributor.author | Miranda Pérez de Alejo, Claudia | |
dc.contributor.author | Miguel Coello, Ana Beatriz | |
dc.contributor.author | Beraza, Marta | |
dc.contributor.author | Di Silvio, Desiré | |
dc.contributor.author | Urkola Arsuaga, Ainhize | |
dc.contributor.author | Sánchez Guisado, María Jesús | |
dc.contributor.author | Aiestaran Zelaia, Irati | |
dc.contributor.author | Fernández Méndez, Laura | |
dc.contributor.author | Martínez Parra, Lydia | |
dc.contributor.author | Ismalaj, Ermal | |
dc.contributor.author | Berra, Edurne | |
dc.contributor.author | Carregal Romero, Susana | |
dc.contributor.author | Ruíz Cabello, Jesús | |
dc.date.accessioned | 2025-02-12T17:51:31Z | |
dc.date.available | 2025-02-12T17:51:31Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Journal of Nanobiotechnology 22 : (2024) // Article ID 709 | es_ES |
dc.identifier.issn | 1477-3155 | |
dc.identifier.uri | http://hdl.handle.net/10810/72656 | |
dc.description.abstract | Background Pulmonary arterial hypertension (PAH) is a severe disease characterized by elevated blood pressure in the pulmonary artery that can ultimately damage the right ventricle of the heart. PAH is pathophysiologically heterogeneous, which makes early diagnosis and treatment difficult. Inflammation is thought to be an important factor in the development and progression of this disease and may explain some of the observed interindividual differences. In the context of both acute and chronic inflammation, neutrophil recruitment to the lung has been suggested as a potential biomarker for studying PAH progression. However, there are currently no specific probes for its non-invasive in vivo detection. The imaging-based gold standard for assessing inflammation is [18F] fluorodeoxyglucose (18F-FDG), which is not cell specific. This highlights the urgent need for more specific molecular probes to support personalized medicine. Methods This study investigated the potential of magnetic nanoradiotracers based on ultrasmall iron oxide nanoparticles, functionalized with N-cinnamoyl-F-(D)L-F-(D)L-F peptide, to detect increased neutrophil infiltration in vivo in different PAH animal models via positron emission tomography. These nanoprobes target formyl peptide receptor 1, which is abundantly expressed in the cell membrane of neutrophils. To assess the benefit of these nanoprobes, their biodistribution was first assessed via magnetic resonance imaging and histology. Then, their lung uptake was compared by positron emission tomography with that of 18F-FDG in two types of PAH animal models with different profiles of inflammation and neutrophil infiltration: monocrotaline and double-hit Sugen-chronic hypoxia PAH rat models. Results Our targeted magnetic nanoradiotracer detected an increase in pulmonary neutrophil infiltration in both PAH models and distinguished between them, which was not possible with 18F-FDG PET. Conclusions This study underscores the importance of targeted imaging in providing an individualized and longitudinal evaluation of heterogeneous and multifactorial diseases such as PAH. The use of targeted multimoda | es_ES |
dc.description.sponsorship | SCR acknowledges the MCIN/AEI 10.13039/501100011033 projects (CNS2023-143944, RYC2020-030241-I, PID2022-142842OB-I00), the Ikerbasque (Basque Foundation for Science) and Ramon Areces Foundation (CIVP21S13151). JRC is funded by MCIN/AEI/10.13039/501100011033 (PID2021-123238OB-I00), the Basque Government under the Elkartek 2024 Program (bmG24), and R&D projects in Health (Grant number 2022333041). SCR and JRC thank IKERBASQUE for sponsoring them. This study was performed under the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency, MDM-2017-0720 (CIC biomaGUNE). We also acknowledge the “Fundación contra la hipertensión pulmonar” for funding (Empathy). The work of EB is supported by the Basque Department of Industry, Tourism, and Trade (Elkartek) and MICINN (PID2019-108112RB-I00 (FEDER/EU); Severo Ochoa Excellence Accreditation MCIN/AEI/10.13039/501100011033 for grant CEX2021‐001136‐S). CIBERES and CIBERONC were co-funded with FEDER funds and by ISCIII. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMC | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/RYC2020-030241-I | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2022-142842OB-I00 | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2021-123238OB-I00 | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2019-108112RB-100 | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/CEX2021‐001136‐S | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.title | Magnetic nanoradiotracers for targeted neutrophil detection in pulmonary arterial hypertension | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. | es_ES |
dc.rights.holder | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.relation.publisherversion | https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-024-03000-7 | es_ES |
dc.identifier.doi | 10.1186/s12951-024-03000-7 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you
give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the
licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder.